选择性及泛PPAR激动剂对实验性脂肪性肝炎和肝脏巨噬细胞的差异作用
该研究在CDAA-HFD和WD喂养的NAFLD小鼠模型中比较泛PPAR激动剂lanifibranor与选择性PPARα/γ/δ激动剂的疗效,发现lanifibranor改善所有组织学特征包括纤维化,并减少肝脏单核细胞来源巨噬细胞浸润,且以PPARδ依赖方式减轻巨噬细胞炎症活化。
要点
- lanifibranor在CDAA-HFD小鼠中改善脂肪性肝炎所有组织学特征包括纤维化,效果合并并超越单PPAR激动剂。
- PPAR激动剂减少肝脏浸润的单核细胞来源巨噬细胞,lanifibranor作用最显著,与脂肪变性和肝炎改善平行。
- lanifibranor以PPARδ依赖方式减轻小鼠和NAFLD患者单核细胞炎症活化,但不直接影响单核细胞募集。
核心结论
- 泛PPAR激动剂lanifibranor结合了选择性PPAR激动剂的益处,可能更有效对抗炎症和疾病进展。
- PPARδ激动和lanifibranor直接调节巨噬细胞活化而非浸润,与PPARα/γ激动剂的代谢益处协同。
研究设计与样本
- 在CDAA-HFD和WD喂养的NAFLD小鼠模型中治疗性给予lanifibranor或选择性PPARα(非诺贝特)、PPARγ(吡格列酮)、PPARδ(GW501516)激动剂。
- 用CCl4诱导急性肝损伤,在分离的肝脏巨噬细胞、棕榈酸刺激的骨髓来源巨噬细胞和NAFLD患者循环单核细胞中研究PPAR对巨噬细胞功能的作用。
主要发现
- lanifibranor改善CDAA-HFD小鼠脂肪性肝炎所有组织学特征包括肝纤维化,合并并超越单PPAR激动剂的特异性效应。
- lanifibranor在3D肝脏生物芯片模型中证实强效抗脂肪变功效。
- PPAR激动剂给药后肝脏浸润的单核细胞来源巨噬细胞减少,lanifibranor尤其显著,即使短期治疗也如此,与脂肪变性和肝炎改善平行。
- lanifibranor在WD模型中同样减少脂肪变性、肝损伤和单核细胞浸润。
- 在急性CCl4模型中,单PPAR或泛PPAR激动剂均不直接影响单核细胞募集。
临床怎么用
- lanifibranor可能通过PPARδ依赖机制直接调节巨噬细胞活化,为NAFLD治疗提供靶点。
- 支持泛PPAR激动剂临床开发,因其结合代谢和抗炎效应。
局限性
- 研究基于小鼠模型和体外细胞实验,人体疗效需临床验证。
- 急性CCl4模型中PPAR激动剂未影响单核细胞募集,提示对急性损伤的巨噬细胞浸润作用有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Peroxisome proliferator-activated receptors (PPARs) are essential regulators of whole-body metabolism, but also modulate inflammation in immune cells, notably macrophages. We compared the effects of selective PPAR agonists to those of the pan-PPAR agonist lanifibranor in non-alcoholic fatty liver disease (NAFLD), and studied isoform-specific effects on hepatic macrophage biology. METHODS: Lanifibranor or selective PPARα (fenofibrate), PPARγ (pioglitazone) and PPARδ (GW501516) agonists were therapeutically administered in choline-deficient, amino acid-defined high-fat diet (CDAA-HFD)- and Western diet (WD)-fed mouse models of NAFLD. Acute liver injury was induced by carbon tetrachloride (CCl4). The role of PPARs on macrophage functionality was studied in isolated hepatic macrophages, bone marrow-derived macrophages stimulated with palmitic acid, and circulating monocytes from patients with NAFLD. RESULTS: Lanifibranor improved all histological features of steatohepatitis in CDAA-HFD-fed mice, including liver fibrosis, thereby combining and exceeding specific effects of the single PPAR agonists. Its potent anti-steatotic efficacy was confirmed in a 3D liver biochip model with primary cells. Infiltrating hepatic monocyte-derived macrophages were reduced following PPAR agonist administration, especially with lanifibranor, even after short-term treatment, paralleling improved steatosis and hepatitis. Lanifibranor similarly decreased steatosis, liver injury and monocyte infiltration in the WD model. In the acute CCl4 model, neither single nor pan-PPAR agonists directly affected monocyte recruitment. Hepatic macrophages isolated from WD-fed mice displayed a metabolically activated phenotype. Lanifibranor attenuated the accompanying inflammatory activation in both murine palmitic acid-stimulated bone marrow-derived macrophages, as well as patient-derived circulating monocytes, in a PPARδ-dependent fashion. CONCLUSION: Pan-PPAR agonists combine the beneficial effects of selective PPAR agonists and may counteract inflammation and disease progression more potently. PPARδ agonism and lanifibranor directly modulate macrophage activation, but not infiltration, thereby synergizing with beneficial metabolic effects of PPARα/γ agonists. LAY SUMMARY: Peroxisome proliferated-activated receptors (PPARs) are essential regulators of metabolism and inflammation. We demonstrated that the pan-PPAR agonist lanifibranor ameliorated all aspects of non-alcoholic fatty liver disease in independent experimental mouse models. Non-alcoholic fatty liver disease and fatty acids induce a specific polarization status in macrophages, which was altered by lanifibranor to increase expression of lipid handling genes, thereby decreasing inflammation. PPAR isoforms have differential therapeutic effects on fat-laden hepatocytes, activated hepatic stellate cells and inflammatory macrophages, supporting the clinical development of pan-PPAR agonists.
引用
- Lefere S, Puengel T, Hundertmark J, et al. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages☆. J Hepatol. 2020. PMID: 32360434. doi:10.1016/j.jhep.2020.04.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。